Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: cogentbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2024 | $14.00 → $8.00 | Outperform → Neutral | Robert W. Baird |
| 2/8/2024 | $11.00 | Buy | Citigroup |
| 12/11/2023 | $5.00 | Outperform → Neutral | Wedbush |
| 12/8/2023 | $18.00 | Overweight | JP Morgan |
| 4/28/2023 | $20.00 | Outperform | Robert W. Baird |
| 3/27/2023 | $28.00 | Buy | H.C. Wainwright |
| 12/14/2022 | $24.00 | Buy | Needham |
| 6/28/2022 | $15.00 | Buy | Guggenheim |
| 11/5/2021 | $25.00 → $31.00 | Buy | HC Wainwright & Co. |
| 10/11/2021 | $25.00 | Buy | HC Wainwright & Co. |
WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming presentations for bezuclastinib at the 64th Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA from December 10-13, 2022. The company will also host a virtual investor event on December 12 that will be accessible via conference call and webcast, with full details to be made available closer to the date. Oral presentation details: Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Nov
All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed patients achieved ≥50% bone marrow mast cell reduction and decreases in blood KIT D816V variant allele fraction (VAF) Bezuclastinib demonstrates favorable initial safety and tolerability profile with no reported periorbital or peripheral edema, cognitive effects or intracranial bleeding events Cogent to host investor conference call and webcast today at 8:00 a.m. ET CAMBRIDGE, Mass. and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biote
Preclinical data highlight company's fourth discovery stage program, a novel potent and selective KRAS(ON) inhibitor Updated preclinical data from CGT6297, Cogent's H1047R mutant-selective PI3Kα inhibitor demonstrates robust inhibition of downstream signaling and efficacy WALTHAM, Mass. and BOULDER, Colo., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the addition of a potent and selective KRAS inhibitor to its pipeline. Preclinical data from this program as well as its newly announced H1047R mutant-selective PI3Kα clinic
413 patients enrolled in PEAK Phase 3 GIST trial, exceeding enrollment target; top-line results expected by end of 2025 PEAK interim futility analysis completed with no changes to study Registration-directed SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) now on track to complete enrollment in Q1 2025; top-line results expected 2H 2025 WALTHAM, Mass. and BOULDER, Colo., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided several updates from the company's ongoing registration-directed clinical trials of its potential best-in-class KIT
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 2Q 2024 with $390 million, sufficient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2024. "Cogent has made tremendous progress in the first half of 2024 and we look forward to continuing to execute on our key priorities across the portfolio," said Andrew Robbins, the Company's Pres
WALTHAM, Mass. and BOULDER, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Company's novel patient reported outcome measure, Mastocytosis Symptom Severity Daily Diary (MS2D2), for use in Part 2 of the registration-directed SUMMIT trial evaluating bezuclastinib in Nonadvanced Systemic Mastocytosis (NonAdvSM) patients. "We recently completed a positive discussion with the FDA on the use of MS2D2 in our SUMMIT trial for Nonadvanced Systemic Mastocytosis patients,"
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains and objective reduction in skin lesions corresponding with symptomatic improvement WALTHAM, Mass. and BOULDER, Colo., June 14, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis (NonAdvSM)
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients
Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment Encouraging long-term safety and tolerability with combination bezuclastinib and sunitinib therapy in Part 1 PEAK Phase 3 guidance accelerated with enrollment completion now expected in 3Q 2024 Company announces new advanced GIST clinical trial sponsored by the Sarcoma Alliance for Research through Collaboration (SARC) and in collaboration with The Life Raft Group and Dana-Farber Cancer Institute WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2024. "Our team made important progress in the first quarter," said Andrew Robbins, the Company's President and Chief Executive Officer. "Based on the
WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company's potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taking place in San Diego, California. "We're excited with the progress we've made on our ErbB2 program and look forward to sharing our differentiated profile at this year's AACR meeting," said Andrew Robbins, Cogent's President and Chief Execut
• UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected by YE 2025 • PEAK Phase 3 study of bezuclastinib + sunitinib in 2nd-line GIST patients on track to complete enrollment by end of 2024; topline results expected by YE 2025 • APEX Part 2 registration-directed study of bezuclastinib in AdvSM patients on track to complete enrollment by end of 2024; topline results expected by mid-2025 • $487 million in pro-forma cash sufficient to fund operations into 2027; includes net proceeds from oversubscribed $225 million February 2024 PIPE
SC 13D/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13D/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13D/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13D/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13G - Cogent Biosciences, Inc. (0001622229) (Subject)
SC 13G - Cogent Biosciences, Inc. (0001622229) (Subject)
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients
WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of Clinical Development. "We are pleased to welcome Dr. Easton to Cogent as we continue to develop bezuclastinib in Systemic Mastocytosis and GIST," said Andrew Robbins, the company's President and Chief Executive Officer. "Dr. Easton is an accomplished physician-scientist who brings a wealth of experience in both early and late-stage clinical development across multiple therapeutic areas. Her backgrou
CAMBRIDGE, Mass. and BOULDER, Colo., May 3, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Evan Kearns as Chief Legal Officer. In his new role, Mr. Kearns will oversee all corporate legal operations for Cogent Biosciences. "I am excited to welcome Evan to the Cogent team as our Chief Legal Officer," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "Evan's expert counsel and proven leadership in ad
CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Todd E. Shegog to its Board of Directors. Todd currently serves as the Chief Financial Officer for Forma Therapeutics and has more than 25 years of financial, operations, corporate strategy, and compliance expertise in the biotechnology and pharmaceutical industries. (PRNewsfoto/Cogent Biosciences, Inc.) "We are pleased to welcome Todd to Cogent Biosciences' Board of Directors," said Andrew Robbins, Chief Executive Officer and President of Cogent Bi
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.
Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Company's novel patient reported outcome measure, Mastocytosis Symptom Severity Daily Diary (MS2D2), for use in Part 2 of the registration-directed SUMMIT trial evaluating bezuclastinib in Nonadvanced Systemic Mastocytosis (NonAdvSM) patients.
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $19 price target.
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Neutral and maintains $10 price target.
PEAK Phase 3 guidance accelerated with enrollment completion now expected in 3Q 2024
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $19 price target.
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.
8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
S-8 - Cogent Biosciences, Inc. (0001622229) (Filer)
10-Q - Cogent Biosciences, Inc. (0001622229) (Filer)
8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
10-Q - Cogent Biosciences, Inc. (0001622229) (Filer)
8-K - Cogent Biosciences, Inc. (0001622229) (Filer)
ARS - Cogent Biosciences, Inc. (0001622229) (Filer)
DEFA14A - Cogent Biosciences, Inc. (0001622229) (Filer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
4 - Cogent Biosciences, Inc. (0001622229) (Issuer)
Robert W. Baird downgraded Cogent Biosciences from Outperform to Neutral and set a new price target of $8.00 from $14.00 previously
Citigroup initiated coverage of Cogent Biosciences with a rating of Buy and set a new price target of $11.00
Wedbush downgraded Cogent Biosciences from Outperform to Neutral and set a new price target of $5.00
JP Morgan initiated coverage of Cogent Biosciences with a rating of Overweight and set a new price target of $18.00
Robert W. Baird initiated coverage of Cogent Biosciences with a rating of Outperform and set a new price target of $20.00
H.C. Wainwright resumed coverage of Cogent Biosciences with a rating of Buy and set a new price target of $28.00
Needham initiated coverage of Cogent Biosciences with a rating of Buy and set a new price target of $24.00
Guggenheim initiated coverage of Cogent Biosciences with a rating of Buy and set a new price target of $15.00
HC Wainwright & Co. reiterated coverage of Cogent Biosciences with a rating of Buy and set a new price target of $31.00 from $25.00 previously
HC Wainwright & Co. initiated coverage of Cogent Biosciences with a rating of Buy and set a new price target of $25.00